Home APIs Beta Drugs Limited
B

Beta Drugs Limited

Profile managed by Bizz Id
India 500+ employees 2005

Description

Listed oncology pharmaceutical company on the NSE and part of the Adley group, developing, manufacturing and marketing anti-cancer finished dosage forms, active ingredients and cosmeceuticals. States more than 135 oncology products across haemato-oncology, uro-oncology and supportive care. Three plants: two formulation sites at Baddi, Himachal Pradesh, and an API plant at Derabassi, Punjab, operated by subsidiary Adley Lab.

Products

121 products
AB-PACLI (paclitaxel protein-bound particles for injectable suspension)

Oncology. Microtubule inhibitor

Finished product (FDF)

Verified on 2026-10-22

Ab-pacli: see suppliers →

ADBEN (Bendamustine Injection)

Oncology. Alkylating agent

Finished product (FDF)

Verified on 2026-10-22

Adben: see suppliers →

ADBIRON (Abiraterone)

Oncology. CYP17 inhibitor

Finished product (FDF)

Verified on 2026-10-22

Adbiron: see suppliers →

ADCARB (Carboplatin)

Oncology. Microtubule inhibitor

Finished product (FDF)

Verified on 2026-10-22

Adcarb: see suppliers →

ADCILIB (Palbociclib)

Oncology. Antineoplastic CDK inhibitor

Finished product (FDF)

Verified on 2026-10-22

Adcilib: see suppliers →

ADCIST (Cisplatin)

Oncology. Alkylating agent

Finished product (FDF)

Verified on 2026-10-22

Adcist: see suppliers →

ADCOV (Leucovorin calcium)

Oncology. Folic acid analogs

Finished product (FDF)

Verified on 2026-10-22

Adcov: see suppliers →

ADCUMIN

Oncology. Chemotherapeutic agent

Finished product (FDF)

Verified on 2026-10-22

Adcumin: see suppliers →

Adcumin Royale Ora Rinz

Oncology. Chemotherapeutic agent (Supportive Care)

Finished product (FDF)

Verified on 2026-10-22

Adcumin Royale Ora Rinz: see suppliers →

ADCYCLO (cyclophosphamide)

Oncology. Synthetic antineoplastic drug

Finished product (FDF)

Verified on 2026-10-22

Adcyclo: see suppliers →

ADFLU (Fludarabine)

Oncology. Antimetabolite agent

Finished product (FDF)

Verified on 2026-10-22

Adflu: see suppliers →

ADGEF (Gefitinib)

Oncology. Kinase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Adgef: see suppliers →

ADGORIF

Oncology. Antineoplastic

Finished product (FDF)

Verified on 2026-10-22

Adgorif: see suppliers →

ADGRAM

Oncology. Antiemetic

Finished product (FDF)

Verified on 2026-10-22

Adgram: see suppliers →

ADLANTE (Lenvatinib)

Oncology. Kinase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Adlante: see suppliers →

ADLEAP (enzalutamide)

Oncology. Androgen receptor inhibitor

Finished product (FDF)

Verified on 2026-10-22

Adleap: see suppliers →

ADLINOD (lenalidomide)

Oncology. Immunomodulatory agent

Finished product (FDF)

Verified on 2026-10-22

Adlinod: see suppliers →

ADMIDE (Bicalutamide)

Oncology. Androgen receptor inhibitor

Finished product (FDF)

Verified on 2026-10-22

Admide: see suppliers →

ADMINE (Imatinib mesylate)

Oncology. Kinase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Admine: see suppliers →

ADNAST (Anastrazole)

Oncology. Aromatase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Adnast: see suppliers →

ADOCTIDE

Oncology. Anti-Neoplastic

Finished product (FDF)

Verified on 2026-10-22

Adoctide: see suppliers →

ADOXI (Docetaxel)

Oncology. Microtubule inhibitor

Finished product (FDF)

Verified on 2026-10-22

Adoxi: see suppliers →

ADPAXIL (Paclitaxel)

Oncology. Microtubule stabilising ability

Finished product (FDF)

Verified on 2026-10-22

Adpaxil: see suppliers →

ADPEM (Pemetrexed Disodium)

Oncology. Folate analog metabolic inhibitor

Finished product (FDF)

Verified on 2026-10-22

Adpem: see suppliers →

ADPLATIN (Oxaliplatin)

Oncology. Topoisomerase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Adplatin: see suppliers →

ADPOMIDE

Oncology. Immunomodulatory agent

Finished product (FDF)

Verified on 2026-10-22

Adpomide: see suppliers →

ADRIB (Doxorubicin)

Oncology. Cytotoxic anthracycline antibiotic

Finished product (FDF)

Verified on 2026-10-22

Adrib: see suppliers →

ADRICN (Epirubicin)

Oncology. Anthracycline topoisomerase II inhibitor

Finished product (FDF)

Verified on 2026-10-22

Adricn: see suppliers →

ADSIDE (Etoposide)

Oncology. Topoisomerase II inhibitor

Finished product (FDF)

Verified on 2026-10-22

Adside: see suppliers →

ADSTEM (Plerixafor injection)

Oncology. Hematopoietic stem cell mobilizer

Finished product (FDF)

Verified on 2026-10-22

Adstem: see suppliers →

ADSTROM (Eltrombopag Tablets)

Oncology. Small molecule TPO receptor agonist

Finished product (FDF)

Verified on 2026-10-22

Adstrom: see suppliers →

ADSUNIB (Sunitinib Malate)

Oncology. Kinase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Adsunib: see suppliers →

ADTHAL (Thalidomide)

Oncology. Immunomodulatory agent

Finished product (FDF)

Verified on 2026-10-22

Adthal: see suppliers →

ADTRINIB (Sorafenib)

Oncology. Kinase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Adtrinib: see suppliers →

ADVIBE

Cosmeceutical. Oral therapy for hormonal imbalance

Finished product (FDF)

Verified on 2026-10-22

Advibe: see suppliers →

ADVIN (Vinorelbine)

Oncology. Vinca alkaloid

Finished product (FDF)

Verified on 2026-10-22

Advin: see suppliers →

ADXATE (Methotrexate Injection)

Oncology. Antimetabolite

Finished product (FDF)

Verified on 2026-10-22

Adxate: see suppliers →

ADXATE-OS

Oncology. Anti-Neoplastic

Finished product (FDF)

Verified on 2026-10-22

Adxate-os: see suppliers →

AFADEL (Afatinib)

Oncology. Kinase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Afadel: see suppliers →

ALZIC

Oncology. Bisphosphonates

Finished product (FDF)

Verified on 2026-10-22

Alzic: see suppliers →

AMGICIN (Gemcitabine)

Oncology. Nucleoside metabolic inhibitor

Finished product (FDF)

Verified on 2026-10-22

Amgicin: see suppliers →

ANASTROZOLE

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Anastrozole: see suppliers →

APREPITANT

Supportive care

DMF under preparation

API (active ingredient)

Verified on 2026-10-22

Aprepitant: see suppliers →

ARBAZ (Cabazitaxel)

Oncology. Microtubule inhibitor

Finished product (FDF)

Verified on 2026-10-22

Arbaz: see suppliers →

AXITINIB

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Axitinib: see suppliers →

AZACITIDINE

Hematology

API (active ingredient)

Verified on 2026-10-22

Azacitidine: see suppliers →

AZTRIKE

Cosmeceutical. Azelaic acid cream

Cosmetic or ingredient

Verified on 2026-10-22

BACINOX

Cosmeceutical. Bacterial skin infections

Cosmetic or ingredient

Verified on 2026-10-22

BEEDAN (Dasatinib Tablets)

Oncology. Kinase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Beedan: see suppliers →

BENDAMUSTINE HYDROCHLORIDE

Hematology

DMF under preparation

API (active ingredient)

Verified on 2026-10-22

Bendamustine: see suppliers →

BETATINIB

Oncology. Anti-Neoplastic

Finished product (FDF)

Verified on 2026-10-22

Betatinib: see suppliers →

BEXINIB (Axitinib)

Oncology. Kinase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Bexinib: see suppliers →

BICALUTAMIDE

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Bicalutamide: see suppliers →

BORTEZOMIB

Hematology

API (active ingredient)

Verified on 2026-10-22

Bortezomib: see suppliers →

BORTIAD (Bortezomib Injection)

Oncology. Proteasome inhibitor

Finished product (FDF)

Verified on 2026-10-22

Bortiad: see suppliers →

Briface Serum

Cosmeceutical. Serum for clearer, brighter skin

Cosmetic or ingredient

Verified on 2026-10-22

BUSFAN (busulfan)

Oncology. Alkylating agent

Finished product (FDF)

Verified on 2026-10-22

Busfan: see suppliers →

CANRIB (Olaparib)

Oncology. PARP inhibitor

Finished product (FDF)

Verified on 2026-10-22

Canrib: see suppliers →

CAPAD (Capecitabine)

Oncology. Nucleoside metabolic inhibitor

Finished product (FDF)

Verified on 2026-10-22

Capad: see suppliers →

CARFIMIB (Carfilzomib Injection)

Oncology. Proteasome inhibitor

Finished product (FDF)

Verified on 2026-10-22

Carfimib: see suppliers →

CAXFILA OS

Oncology. Supportive Care

Finished product (FDF)

Verified on 2026-10-22

Caxfila Os: see suppliers →

CERITINIB

Under development

API (active ingredient)

Verified on 2026-10-22

Ceritinib: see suppliers →

CLAXNOVA

Oncology. Anti-Neoplastic

Finished product (FDF)

Verified on 2026-10-22

Claxnova: see suppliers →

CLINZAP

Cosmeceutical. Anti-acne gel

Cosmetic or ingredient

Verified on 2026-10-22

DACENZA

Oncology. Anti-Neoplastic

Finished product (FDF)

Verified on 2026-10-22

Dacenza: see suppliers →

DASATINIB

Hematology

API (active ingredient)

Verified on 2026-10-22

Dasatinib: see suppliers →

DOCETAXEL TRIHYDRATE

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Docetaxel: see suppliers →

ELTROMBOPAG OIAMINE

Supportive care

API (active ingredient)

Verified on 2026-10-22

Eltrombopag Oiamine: see suppliers →

ENZALUTAMIDE

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Enzalutamide: see suppliers →

ERIBULIN

Under development

API (active ingredient)

Verified on 2026-10-22

Eribulin: see suppliers →

ERLOTAD (Erlotinib)

Oncology. Kinase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Erlotad: see suppliers →

ERLOTINIB HYDROCHLORIDE

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Erlotinib: see suppliers →

FISTENT (Fulvestrant)

Oncology. Estrogen receptor antagonist

Finished product (FDF)

Verified on 2026-10-22

Fistent: see suppliers →

FLUDARABINE PHOSPHATE

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Fludarabine: see suppliers →

FORTH

Oncology. Iron replacement

Finished product (FDF)

Verified on 2026-10-22

Forth: see suppliers →

FOS-APREPITANT

Supportive care

DMF under preparation

API (active ingredient)

Verified on 2026-10-22

Fos-aprepitant: see suppliers →

FULVESTRANT

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Fulvestrant: see suppliers →

GEFITINIB

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Gefitinib: see suppliers →

GEMCITABINE HYDROCHLORIDE

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Gemcitabine: see suppliers →

HERTINIB (Lapatinib)

Oncology. Kinase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Hertinib: see suppliers →

HUMIDA

Cosmeceutical. Dry skin hydration

Cosmetic or ingredient

Verified on 2026-10-22

HYDROXYUREA

Hematology; supportive care

API (active ingredient)

Verified on 2026-10-22

Hydroxyurea: see suppliers →

IBRUTINIB

Hematology

Under development

API (active ingredient)

Verified on 2026-10-22

Ibrutinib: see suppliers →

IDERA

Cosmeceutical. Broad-spectrum systemic antifungal

Finished product (FDF)

Verified on 2026-10-22

Idera: see suppliers →

IMATINIB MESYLATE

Hematology

API (active ingredient)

Verified on 2026-10-22

Imatinib: see suppliers →

INOTAD (Irinotecan)

Oncology. Topoisomerase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Inotad: see suppliers →

IRINOTECAN

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Irinotecan: see suppliers →

KABONIB (Cabozantinib)

Oncology. Kinase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Kabonib: see suppliers →

KYLONIB (Nilotinib Capsule)

Oncology

Finished product (FDF)

Verified on 2026-10-22

Kylonib: see suppliers →

L-Asgen (L-Asparaginase)

Oncology. Antineoplastic

Finished product (FDF)

Verified on 2026-10-22

L-Asgen: see suppliers →

La'Thrix

Cosmeceutical. Loss of hair pigmentation

Cosmetic or ingredient

Verified on 2026-10-22

LAPATANIB DITOSYLATE

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Lapatanib: see suppliers →

LENALIDOMIDE

Hematology

API (active ingredient)

Verified on 2026-10-22

Lenalidomide: see suppliers →

LENVATINIB

Oncology: solid tumor

DMF under preparation (as LENVATINIB MESYLATE)

API (active ingredient)

Verified on 2026-10-22

Lenvatinib: see suppliers →

LETRAFEM (Letrozole)

Oncology. Aromatase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Letrafem: see suppliers →

MDS Plus (Azacitidine tablets)

Oncology. Nucleoside metabolic inhibitor

Finished product (FDF)

Verified on 2026-10-22

MDS Plus: see suppliers →

MDS-O (Azacitidine tablets)

Oncology. Nucleoside metabolic inhibitor

Finished product (FDF)

Verified on 2026-10-22

MDS-O: see suppliers →

METHOTREXATE

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Methotrexate: see suppliers →

NINTEDANIB

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Nintedanib: see suppliers →

Nupellis Day Cream

Cosmeceutical. Day cream

Cosmetic or ingredient

Verified on 2026-10-22

Nupellis Night Cream

Cosmeceutical. Night cream, deep hydration

Cosmetic or ingredient

Verified on 2026-10-22

Nupellis Retinol Serum

Cosmeceutical. Anti-aging serum with encapsulated retinol

Cosmetic or ingredient

Verified on 2026-10-22

NUSPLASH

Cosmeceutical. Acne, rosacea, atopic dermatitis

Cosmetic or ingredient

Verified on 2026-10-22

PALBOCICLIB

Under development

API (active ingredient)

Verified on 2026-10-22

Palbociclib: see suppliers →

PAZOPANIB

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Pazopanib: see suppliers →

PAZOTAB (Palbociclib Hydrochloride)

Oncology. Tyrosine kinase inhibitor

Finished product (FDF)

Verified on 2026-10-22

Pazotab: see suppliers →

PEG-ADRIB

Oncology. Anti-Neoplastic

Finished product (FDF)

Verified on 2026-10-22

Peg-adrib: see suppliers →

Peg-Lasgen (pegaspargase)

Oncology. Antineoplastic

Finished product (FDF)

Verified on 2026-10-22

Peg-Lasgen: see suppliers →

PEMETREXED DISODIUM HEPTAHYDRATE

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Pemetrexed: see suppliers →

PLERIXAFOR

Hematology

API (active ingredient)

Verified on 2026-10-22

Plerixafor: see suppliers →

RECAPRO

Cosmeceutical. Topical solution for hair loss

Cosmetic or ingredient

Verified on 2026-10-22

RUCAPARIB

Oncology: solid tumor

API (active ingredient)

Verified on 2026-10-22

Rucaparib: see suppliers →

SENSIBAR

Cosmeceutical. Syndet cleansing bar

Cosmetic or ingredient

Verified on 2026-10-22

SORAFENIB TOSYLATE

Oncology: solid tumor

DMF under preparation

API (active ingredient)

Verified on 2026-10-22

Sorafenib: see suppliers →

SUNITINIB

Oncology: solid tumor

DMF under preparation

API (active ingredient)

Verified on 2026-10-22

Sunitinib: see suppliers →

Temozad (Temozolomide)

Oncology. Alkylating agent

Finished product (FDF)

Verified on 2026-10-22

Temozad: see suppliers →

TEMOZOLOMIDE

Oncology: solid tumor

DMF under preparation

API (active ingredient)

Verified on 2026-10-22

Temozolomide: see suppliers →

TRIODELTA

Oncology. Supportive Care

Finished product (FDF)

Verified on 2026-10-22

Triodelta: see suppliers →

URTICALM

Cosmeceutical. Allergic reactions

Cosmetic or ingredient

Verified on 2026-10-22

UVIREX

Cosmeceutical. Melasma

Cosmetic or ingredient

Verified on 2026-10-22

ZOLEDRONIC ACID

Supportive care

DMF under preparation

API (active ingredient)

Verified on 2026-10-22

Zoledronic Acid: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free